Stakeholder Update: COVID 19

Medicaid and CHIP Services
August 5, 2021
Stakeholder Session Update

• Beginning May 6, 2021, HHSC will post pre-recorded sessions monthly.

• These sessions will continue to share information with stakeholders about the implementation of various Medicaid/CHIP flexibilities in response to the COVID-19 pandemic.

• HHSC may return to weekly sessions as needed if there are changes to the public health emergency.
Medicaid & CHIP Flexibilities

Kellie Dees, Senior Advisor
MCS Policy and Program
Medicaid & CHIP Flexibilities

- Many Medicaid and CHIP flexibilities have been extended through **August 31, 2021**, unless the federal Public Health Emergency ends sooner.
- HHSC will provide more information if there are changes.
Medicaid & CHIP Flexibilities (cont.)

Information on the flexibilities and extensions can be found on the following webpages:

- HHS Provider (PL) and Information (IL) letters (http://apps.hhs.texas.gov/providers/communications/letters.cfm)
The following flexibility is now set to end by August 31, 2021:

• Extending assessments for STAR Kids age out populations who transition into a new program once a new assessment can be done (if applicable).
COVID-19 Updates

Rachel Roedl, Program Specialist IV
Medical Benefits Policy
COVID-19 Updates

Addition of Monoclonal Antibody Therapy Procedure Codes M0247, Q0247 and Q0244 Approved for the Treatment of COVID-19 Through Emergency Use Authorization

- On May 26, 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy, Sotrovimab, for the treatment of mild-to-moderate COVID-19.

- On June 3, 2021, the FDA issued a revised EUA for Regeneron’s COVID-19 monoclonal antibody combination product casirivimab and imdevimab. The updated EUA includes a new dosing regimen (1200 mg vs. 2400 mg).
COVID-19 Updates (cont.)

• Effective June 18, 2021, for dates of service on or after May 26, 2021, procedure codes M0247 (administration of sotrovimab) and Q0247 (sotrovimab) have been added for Texas Medicaid and the Children with Special Health Care Needs (CSHCN) Services Program.

• Effective June 18, 2021, for dates of service on or after June 3, 2021, procedure code Q0244 (casirivimab and imdevimab with updated dosing regimen) has been added as informational for Texas Medicaid and the CSHCN Services Program.
COVID-19 Updates (cont.)

• The Food and Drug Administration (FDA) approved the use of these monoclonal antibody therapy drugs for treatment of mild-to-moderate COVID-19.

• Procedure code Q0244 is informational only while being distributed to providers free of charge effective June 3, 2021.

• Procedure codes M0247 and Q0247 are benefits for clients who are 12 years of age and older, weigh at least 40kg, and restricted to diagnosis code U071.
COVID-19 Updates (cont.)

- Procedure codes M0247 and Q0247 are benefits for the following providers and places of service:

<table>
<thead>
<tr>
<th>Place of Service</th>
<th>Provider Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office</td>
<td>Physician, Physician Groups, Physician Assistant, Nurse Practitioner, Clinical Nurse Specialist</td>
</tr>
<tr>
<td>Outpatient Hospital</td>
<td>Hospital Providers</td>
</tr>
</tbody>
</table>

**Note:** Procedure codes M0247 and Q0247 will not be reimbursed until expenditures are approved and the rates are adopted by Texas Medicaid. Providers will be notified of any benefit changes in a future article.
COVID-19 Updates (cont.)

• Services provided before the expenditures are approved will receive the following explanation of benefits (EOB) 02008 notification:

“This procedure code has been approved as a benefit pending the approval of expenditures. Providers will be notified of the effective dates of service in a future notification if expenditures are approved.”
COVID-19 Updates (cont.)

• For more information call:
  • TMHP Contact Center at 800-925-9126
  • TMHP-CSHCN Services Program Contact Center at 800-568-2413.

COVID-19 Updates (cont.)

Reimbursement Rate Updates for COVID-19 Administration Procedure Codes M0243 and M0245 Effective May 6, 2021

• Effective June 8, 2021, for dates of service on or after May 6, 2021, the reimbursement rates for COVID-19 monoclonal antibodies and their administration through procedure codes M0243 and M0245 will be updated for Texas Medicaid and the Children with Special Health Care Needs (CSHCN) Services Program.

• To view the updates, click COVID-19 Monoclonal Antibodies and Administration Code M0243 and M0245
COVID-19 Updates (cont.)

• Affected claims, if any are identified, will be reprocessed.
  • Providers are not required to appeal the claims unless they are denied for additional reasons after the claims reprocessing is completed.

• For more information call:
  • TMHP Contact Center at 800-925-9126
  • TMHP-CSHCN Services Program Contact Center at 1-800-568-2413.

LTCR Updates

Tahoe Fintel, Senior Policy Specialist
LTCR Policy, Rules & Training
LTCR Updates

Regulatory Update: Emergency Rules

• Extended on 7/20: Mitigation rules for TxHmL
• Extended on 7/26: Screening rules for HCSSA, DAHS, PPECC
• Effective on 8/6: mitigation rules for ALF

Rule Suspensions Ending

• Effective 8/3: ALF right to receive visitors; ICF/IID 3-day leave
• Other suspensions end in 30, 60, and 90 days—see alert from 8/3
COVID-19 Response

Communication Channels

**Clients**
- COVID section on HHS site
- Health plan channels and providers

**Providers**
- COVID section on HHS site
- COVID section on TMHP site
- Health plan channels

+ Update calls

Submit questions to: Medicaid_COVID_Questions@hhs.texas.gov
Thank You!

Next update: September 2, 2021